Elekta eyes Turkish radiology market with acquisition of Mesi Medikal

July 24, 2014 By Arezu Sarvestani Leave a Comment

AMIC looks to down-classify brachytherapy’s FDA status

February 24, 2014 By Arezu Sarvestani Leave a Comment

AMIC aims to shift brachytherapy to lower-risk FDA status

Washington-based Advanced Medical Isotope Corp. is evaluating its options for U.S. market approval of its proprietary brachytherapy cancer product, the company announced.

Breast cancer: Judge stays C.R. Bard suit against Hologic over Mammosite device

February 7, 2013 By MassDevice staff Leave a Comment

A federal judge in Delaware put a patent infringement spat between C.R. Bard subsidiary SenoRx and Hologic (NSDQ:HOLX) on hold for 90 days last week.

iCad soars on Medicare reimbursement nod | Wall Street Beat

November 5, 2012 By MassDevice staff Leave a Comment

iCad (NSDQ:ICAD) shares nearly doubled their value on Wall Street today after the medical device company said the Centers for Medicare & Medicaid approved a big increase in the reimbursement rate for its Xoft Axxent brachytherapy device.

Cancer research: Varian awards $100k for radiation therapy registry

November 1, 2012 By MassDevice staff Leave a Comment

Varian Medical Systems (NYSE:VAR), a medical device and software manufacturer focused on radiation-based cancer treatment, awarded a $100,000 grant to the American Board of Radiology Foundation to support a national brachytherapy registry.

Elekta Completes the Acquisition of Nucletron

September 15, 2011 By MassDevice Leave a Comment

Elekta AB (publ) (STO:EKTAB) today announced it has successfully
completed its acquisition of Nucletron, the world leader in
brachytherapy treatment planning and delivery. Through the combination
Elekta will offer a complete range of radiotherapy planning and delivery
technologies. As the market leader in Europe and with strong positions
in North America and Asia, Elekta will enhance the combined ability to
meet the clinical needs of cancer patients and health care providers
throughout the world.

“Now we have successfully completed the acquisition and we are very
enthusiastic about building a broader, stronger and highly complementary
range of cutting-edge cancer care solutions”

iCad sued for device acquired in Xoft Inc. acquisition

March 10, 2011 By Dave Price Leave a Comment

Xoft Inc. could turn out to be a lot more expensive for iCad (NSDQ:ICAD) than the $1 million in cash and the 8.47 million shares of stock it paid for the oncology device manufacturer late last year.

Theragenics swings to Q4, 2009 black

February 11, 2010 By MassDevice staff Leave a Comment

Theragenics Corp. (NYSE:TGX) posted fourth-quarter sales of $18.7 million for the three months ended Dec. 31, 2009, up 3.2 percent compared with $18.1 million during the same period in 2008. Net income was $389,000, compared with net losses of $62.5 million during Q4 2008: